LB Pharmaceuticals announces positive schizophrenia trial data
2025年1月15日 · LB Pharmaceuticals, a clinical-stage biopharmaceutical company focused on psychiatric disease therapies, announced positive results from its Phase II NOVA 1 trial of LB …
New study explores safer antidepressants for pregnant women
2025年1月27日 · A new study suggests that targeting serotonin in the gut, rather than the brain, could lead to antidepressants with fewer side effects. Mood disorders, including depression …
Immuno-oncology innovations redefining cancer treatment in 2024
2024年1月23日 · What innovative approaches and technologies are anticipated to reshape immuno-oncology treatments in 2024? Immuno-oncology, notably through checkpoint …
The art and science of drug formulation - Drug Target Review
2024年8月9日 · Drug formulation is a cornerstone of modern medicine, turning raw active ingredients into consumable, effective therapies. This critical phase in drug development …
New AI model may enable more targeted prostate cancer treatment
2024年10月30日 · Based on MRI scans from 732 prostate cancer patients, the AI model identified the edges of 85 percent of the most radiologically aggressive lesions.
How AI will reshape pharma in 2025 - drugtargetreview.com
2024年12月20日 · Discover the impact of AI on pharmaceutical drug development. Find out how AI and machine learning are reshaping the industry and its future.
FDA greenlights AI-developed drug targeting solid tumors
2024年12月4日 · Insilico Medicine's AI-designed drug ISM5939, targeting ENPP1, receives FDA IND clearance for solid tumour treatment.
Tessera Therapeutics: addressing Alpha-1 Antitrypsin Deficiency
2024年6月18日 · At this year’s ASGCT conference, Tessera shared progress on its RNA Gene Writers™, including promising data in preclinical models of AATD.
Boltz-1: A new open-source AI tool for drug discovery
2024年12月31日 · MIT’s new open-source AI model, Boltz-1, could transform drug discovery by accurately predicting protein structures, offering global access to researchers.
Drug candidates with blockbuster potential for CNS diseases
2024年9月19日 · In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. …